Mercado mundial de neoplasias hematológicas: tendencias de la industria y pronóstico hasta 2029

Análisis y tamaño del mercado

En los últimos años, se prevé que el mercado de neoplasias hematológicas crezca rápidamente durante el período de pronóstico. Según la hoja de información de Globocan 2020, se anticiparon 19,292,789 nuevos casos de cáncer identificados a nivel mundial, con aproximadamente 9,958,133 muertes relacionadas con el cáncer. Además, la Agencia Internacional para la Investigación del Cáncer (IARC) predice que para 2040, la incidencia mundial de cáncer habría aumentado a 27,5 millones de casos nuevos y 16,3 millones de muertes. Las neoplasias hematológicas, a menudo conocidas como cáncer hematológico, son cada vez más comunes en todo el mundo. Según el Instituto Nacional del Cáncer, el cáncer hematológico es el quinto cáncer más frecuente en todo el mundo y la segunda causa principal de muerte por cáncer en los Estados Unidos. Los investigadores estiman que la incidencia de neoplasias hematológicas aumentará aún más en los próximos años, lo que resultará en una mayor demanda de tratamiento, lo que afectará significativamente al mercado de neoplasias hematológicas.

Data Bridge Market Research analiza que el mercado de neoplasias hematológicas se valoró en USD 59,45 mil millones en 2021 y se espera que alcance los USD 138,99 mil millones para 2029, registrando una CAGR del 11,20% durante el período de pronóstico de 2022 a 2029. El informe de mercado curado por el equipo de Data Bridge Market Research incluye un análisis experto en profundidad, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Definición de mercado

Los cánceres de las células productoras de sangre, como el linfoma, la leucemia y el mieloma múltiple, se denominan neoplasias hematológicas. Las plaquetas, los glóbulos rojos (RBC) y los glóbulos blancos (WBC), todos los cuales surgen de las células madre y progenitoras hematopoyéticas en la médula ósea, son responsables del transporte de oxígeno, la coagulación de las heridas y la protección inmunitaria. La microscopía , la citogenética, la inmunofenotipificación, la citometría de flujo, la hibridación in situ con fluorescencia (FISH), la reacción en cadena de la polimerasa (PCR) y el perfil de expresión génica se utilizan para diagnosticar las neoplasias hematológicas.

Alcance del informe y segmentación del mercado

Hematologic Malignancies Market Dynamics

Drivers

• Increasing prevalence of hematological cancer

The rising prevalence of hematological cancer is estimated to enhance the hematologic malignancies market's growth rate. Blood cancer is becoming more common, and people are becoming more aware of the disease's risk at an earlier stage. These are the main drivers driving the market. According to the Leukemia and Lymphoma Society, about one person in the United States is diagnosed with blood cancer every three minutes (LLS). Furthermore, the International Agency for Research on Cancer estimates that 10.1 lakh new cases were diagnosed in 2020, with 7 lakh deaths due to Hematologic Malignancies.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of hematologic malignancies market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

• Advancement in immunohistochemistry (IHC)

Hematologic malignancies can now be accurately detected by exposing tissue samples to diverse antibodies directed against cell molecules and antigens, thanks to developments in immunohistochemistry (IHC). This in turn, estimated to enhance the market's expansion during the forecast period of 2022-2029.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the hematologic malignancies market. Additionally, changing lifestyle of people and rising geriatric population will result in the expansion of hematologic malignancies market.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the hematologic malignancies market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate. The advent of new and more efficient diabetic treatment and monitoring products is estimated to boost the market's growth rate in the future. 

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for the hematologic malignancies market growth during the forecast period.

Restraints/Challenges

On the other hand, high cost associated with the treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the hematologic malignancies market. Additionally, strict regulatory approvals of cancer therapeutics and lack of awareness among people about different types of cancer will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This hematologic malignancies market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hematologic malignancies market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Hematologic malignancies market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Hematologic Malignancies Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. The COVID-19 outbreak had touched every element of cancer care and research, as screening and oncology care services were categorized as low-priority services in various nations throughout the world. Furthermore, various local and national-level limitations on the movement of persons and goods imposed by public and private authorities were shown to severely disrupt the pharmaceutical products and ingredients supply chain, hampering the hematologic malignancies market's growth. Also, due to pandemic, the temporary closure of numerous academic institutes and difficulty in delivering post-sales services had resulted in a reduced supply of cancer products to end users.

Recent Development

• In April 2021, U.S. Food and Drug Administration (FDA) had granted orphan drug designation to CA-4948. It is a small-molecular inhibitor that targets an oncogenic isoform of a gene which is mainly expressed in individuals with acute myeloid leukaemia and myelodysplastic syndrome. According to Curis, Inc., Receiving orphan drug classification is a significant step forward in the company's objective to reduce or prevent cancer progression in patients with uncommon hematologic malignancies.
• In February 2021, TG Therapeutics Inc. had announced accelerated approval of U.S. Food and Drug Administration (FDA) for its UKONIQ (umbralisib). It is an oral, once-daily inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1 (CK1) epsilon which is used for treating adult patients suffering from relapsed or refractory marginal zone lymphoma (MZL) and adult patients with relapsed or refractory follicular lymphoma (FL).

Global Hematologic Malignancies Market Scope

The hematologic malignancies market is segmented on the basis of type, therapy, diagnosis, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Leukaemia
• Lymphoma
• Myeloma

Therapy Type

• Chemotherapy
• Immunotherapy
• Targeted Therapy
  • Tyrosine kinase inhibitors
  • Proteasome inhibitor
  • B-cell lymphoma-2 protein inhibitor
  • Isocitrate dehydrogenase-1 inhibitor
  • Hedgehog pathway inhibitor
  • Others

Diagnosis

• Blood Tests
• Biopsy
• Imaging Tests
  •  X-ray
  • Magnetic resonance imaging (MRI)
  • Positron Emission Tomography (PET)
• Others

Dosage form

• Tablets
• Capsules
• Injections
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Hematologic Malignancies Market Regional Analysis/Insights

The hematologic malignancies market is analysed and market size insights and trends are provided by country, type, therapy, diagnosis, dosage form, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Hematologic malignancies market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the hematologic malignancies market because of the growing number of research and development activities and rising healthcare expenditure will further propel the market's growth rate in this region. Additionally, growing prevalence of blood cancer and rising geriatric population will further influence the market's growth rate in this region

Asia-Pacific are expected to grow during the forecast period due to surging number of generic manufacturers and increasing penetration of novel cancer drugs in this region. Also, the development of healthcare infrastructure and increasing disposable income will further propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Hematologic Malignancies Market Share Analysis

El panorama competitivo del mercado de neoplasias hematológicas proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia global, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, la amplitud y la variedad de productos, el dominio de las aplicaciones. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en relación con el mercado de neoplasias hematológicas.

Algunos de los principales actores que operan en el mercado de neoplasias hematológicas son:

• F. Hoffmann-La Roche Ltd. (Suiza)
• Mylan NV (Estados Unidos)
• Teva Pharmaceutical Industries Ltd. (Irlanda)
• Sanofi (Francia)
• Pfizer Inc. (Estados Unidos)
• GlaxoSmithKline plc (Reino Unido)
• Novartis AG (Suiza)
• Bayer AG (Alemania)
• Eli Lilly and Company (Estados Unidos)
• Merck & Co., Inc. (Estados Unidos)
• Allergan (Irlanda)
• AstraZeneca (Reino Unido)
• AbbVie Inc. (Estados Unidos)
• Johnson & Johnson Private Limited (Estados Unidos)
• Cipla Inc. (Estados Unidos)  
• Abbott (Estados Unidos)
• Merck KGaA (Alemania)
• LEO Pharma A/S (Dinamarca)
• Bausch Health Companies Inc. (Canadá)
• Industrias farmacéuticas Sun Ltd. (India)
• Aurobindo Pharma (India)
• Lupino (India)
• Hikma Pharmaceuticals PLC (Reino Unido)
• Fresenius Kabi AG (Alemania)
• Amneal Pharmaceuticals LLC. (Estados Unidos)

SKU-53751